1.Human ESC-derived vascular cells promote vascular regeneration in a HIF-1α dependent manner.
Jinghui LEI ; Xiaoyu JIANG ; Daoyuan HUANG ; Ying JING ; Shanshan YANG ; Lingling GENG ; Yupeng YAN ; Fangshuo ZHENG ; Fang CHENG ; Weiqi ZHANG ; Juan Carlos Izpisua BELMONTE ; Guang-Hui LIU ; Si WANG ; Jing QU
Protein & Cell 2024;15(1):36-51
Hypoxia-inducible factor (HIF-1α), a core transcription factor responding to changes in cellular oxygen levels, is closely associated with a wide range of physiological and pathological conditions. However, its differential impacts on vascular cell types and molecular programs modulating human vascular homeostasis and regeneration remain largely elusive. Here, we applied CRISPR/Cas9-mediated gene editing of human embryonic stem cells and directed differentiation to generate HIF-1α-deficient human vascular cells including vascular endothelial cells, vascular smooth muscle cells, and mesenchymal stem cells (MSCs), as a platform for discovering cell type-specific hypoxia-induced response mechanisms. Through comparative molecular profiling across cell types under normoxic and hypoxic conditions, we provide insight into the indispensable role of HIF-1α in the promotion of ischemic vascular regeneration. We found human MSCs to be the vascular cell type most susceptible to HIF-1α deficiency, and that transcriptional inactivation of ANKZF1, an effector of HIF-1α, impaired pro-angiogenic processes. Altogether, our findings deepen the understanding of HIF-1α in human angiogenesis and support further explorations of novel therapeutic strategies of vascular regeneration against ischemic damage.
Humans
;
Vascular Endothelial Growth Factor A/metabolism*
;
Endothelial Cells/metabolism*
;
Transcription Factors/metabolism*
;
Gene Expression Regulation
;
Hypoxia/metabolism*
;
Cell Hypoxia/physiology*
2.Iridociliary Body Metastasis of Atypical Carcinoid: Case Management with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Yang ZHANG ; Ai-Ling BIAN ; Rong-Ping DAI
Chinese Medical Sciences Journal 2023;38(4):305-308
We report a rare case involving a 52-year-old female diagnosed with an atypical bronchial carcinoid tumor with metastases to the mediastinum, hilar lymph nodes, breast, and pancreas. In additional, the patient had metastases to the iris and ciliary body, resulting in progressive vision loss in her left eye. Treatment was successful by intravitreal injections of anti-vascular endothelial growth factor.
Humans
;
Female
;
Middle Aged
;
Endothelial Growth Factors
;
Intravitreal Injections
;
Case Management
;
Carcinoid Tumor/pathology*
3.The Circadian System Is Essential for the Crosstalk of VEGF-Notch-mediated Endothelial Angiogenesis in Ischemic Stroke.
Yuxing ZHANG ; Xin ZHAO ; Chun GUO ; Ying ZHANG ; Fukang ZENG ; Qian YIN ; Zhong LI ; Le SHAO ; Desheng ZHOU ; Lijuan LIU
Neuroscience Bulletin 2023;39(9):1375-1395
Ischemic stroke is a major public health problem worldwide. Although the circadian clock is involved in the process of ischemic stroke, the exact mechanism of the circadian clock in regulating angiogenesis after cerebral infarction remains unclear. In the present study, we determined that environmental circadian disruption (ECD) increased the stroke severity and impaired angiogenesis in the rat middle cerebral artery occlusion model, by measuring the infarct volume, neurological tests, and angiogenesis-related protein. We further report that Bmal1 plays an irreplaceable role in angiogenesis. Overexpression of Bmal1 promoted tube-forming, migration, and wound healing, and upregulated the vascular endothelial growth factor (VEGF) and Notch pathway protein levels. This promoting effect was reversed by the Notch pathway inhibitor DAPT, according to the results of angiogenesis capacity and VEGF pathway protein level. In conclusion, our study reveals the intervention of ECD in angiogenesis in ischemic stroke and further identifies the exact mechanism by which Bmal1 regulates angiogenesis through the VEGF-Notch1 pathway.
Rats
;
Animals
;
Vascular Endothelial Growth Factor A/pharmacology*
;
Brain Ischemia/metabolism*
;
Ischemic Stroke
;
Signal Transduction
;
ARNTL Transcription Factors/pharmacology*
;
Neovascularization, Physiologic/physiology*
4.Effect of hypoxia on HIF -1 α/MDR1/VEGF expression in gastric cancer cells treated with 5 -fluorouracil.
Lu WANG ; Wei XING ; Jin QI ; Yongyan LU ; Linbiao XIANG ; Yali ZHOU
Journal of Central South University(Medical Sciences) 2022;47(12):1629-1636
OBJECTIVES:
Fluorouracil chemotherapeutic drugs are the classic treatment drugs of gastric cancer. But the problem of drug resistance severely limits their clinical application. This study aims to investigate whether hypoxia microenvironment affects gastric cancer resistance to 5-fluorouracil (5-FU) and discuss the changes of gene and proteins directly related to drug resistance under hypoxia condition.
METHODS:
Gastric cancer cells were treated with 5-FU in hypoxia/normoxic environment, and were divided into a Normoxic+5-FU group and a Hypoxia+5-FU group. The apoptosis assay was conducted by flow cytometry Annexin V/PI double staining. The real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were used to detect the expression level of hypoxia inducible factor-1α (HIF-1α), multidrug resistance (MDR1) gene, P-glycoprotein (P-gp), and vascular endothelial growth factor (VEGF) which were related to 5-FU drug-resistance. We analyzed the effect of hypoxia on the treatment of gastric cancer with 5-FU.
RESULTS:
Compared with the Normoxic+5-FU group, the apoptosis of gastric cancer cells treated with 5-FU in the Hypoxia+5-FU group was significantly reduced (P<0.05), and the expression of apoptosis promoter protein caspase 8 was also decreased. Compared with the the Normoxic+5-FU group, HIF-1α mRNA expression in the Hypoxia+5-FU group was significantly increased (P<0.05), and the mRNA and protein expression levels of MDR1, P-gp and VEGF were also significantly increased (all P<0.05). The increased expression of MDR1, P-gp and VEGF had the same trend with the expression of HIF-1α.
CONCLUSIONS
Hypoxia is a direct influencing factor in gastric cancer resistance to 5-FU chemotherapy. Improvement of the local hypoxia microenvironment of gastric cancer may be a new idea for overcoming the resistance to 5-FU in gastric cancer.
Humans
;
Fluorouracil/therapeutic use*
;
Vascular Endothelial Growth Factor A/metabolism*
;
Stomach Neoplasms/drug therapy*
;
Drug Resistance, Multiple
;
Vascular Endothelial Growth Factors/metabolism*
;
Hypoxia
;
ATP Binding Cassette Transporter, Subfamily B/genetics*
;
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics*
;
Cell Line, Tumor
;
Cell Hypoxia
;
RNA, Messenger/metabolism*
;
Hypoxia-Inducible Factor 1, alpha Subunit/genetics*
;
Tumor Microenvironment
5.Medication law and mechanism of traditional Chinese medicine in prevention and treatment of epidemic diseases: based on traditional Chinese medicine theory of cold pestilence.
Ze-Yu LI ; Er-Wei HAO ; Rui CAO ; Si LIN ; Shu-Ying CHEN ; Xian-Ting HUANG ; Wan-Ru XU ; Xiao-Tao HOU ; Jia-Gang DENG
China Journal of Chinese Materia Medica 2022;47(17):4765-4777
Epidemic diseases have caused huge harm to the society. Traditional Chinese medicine(TCM) has made great contributions to the prevention and treatment of them. It is of great reference value for fighting diseases and developing drugs to explore the medication law and mechanism of TCM under TCM theory. In this study, the relationship between the TCM theory of cold pestilence and modern epidemic diseases was investigated. Particularly, the the relationship of coronavirus disease 2019(COVID-19), severe acute respiratory syndrome(SARS), and influenza A(H1 N1) with the cold pestilence was identified and analyzed. The roles of TCM theory of cold pestilence in preventing and treating modern epidemic diseases were discussed. Then, through data mining and textual research, prescriptions for the treatment of cold pestilence were collected from major databases and relevant ancient books, and their medication laws were examined through analysis of high-frequency medicinals and medicinal pairs, association rules analysis, and cluster analysis. For example, the prescriptions with high confidence levels were identified: "Glycyrrhizae Radix et Rhizoma-Bupleuri Radix-Paeoniae Radix Alba" "Glycyrrhizae Radix et Rhizoma-Pinelliae Rhizoma-Bupleuri Radix", and TCM treatment methods with them were analyzed by clustering analysis to yield the medicinal combinations: "Zingiberis Rhizoma-Aconiti Lateralis Radix Praeparata-Ginseng Radix et Rhizoma" "Poria-Atractylodis Macrocephalae Rhizoma" "Cinnamomi Ramulus-Asari Radix et Rhizoma" "Citri Reticulatae Pericarpium-Perillae Folium" "Pinelliae Rhizoma-Magnoliae Officinalis Cortex-Atractylodis Rhizoma" "Paeoniae Radix Alba-Angelicae Sinensis Radix-Glycyrrhizae Radix et Rhizoma-Bupleuri Radix-Scutellariae Radix-Rhizoma Zingiberis Recens" "Ephedrae Herba-Armeniacae Semen Amarum-Gypsum Fibrosum" "Chuanxiong Rhizoma-Notopterygii Rhizoma et Radix-Angelicae Dahuricae Radix-Platycodonis Radix-Saposhnikoviae Radix". Then, according to the medication law for cold pestilence, the antiviral active components of medium-frequency and high-frequency medicinals were retrieved. It was found that these components exerted the antiviral effect by inhibiting virus replication, regulating virus proteins and antiviral signals, and suppressing protease activity. Based on network pharmacology, the mechanisms of the medicinals against severe acute respiratory syndrome coronavirus(SARS-CoV), 2019 novel coronavirus(2019-nCoV), and H1 N1 virus were explored. It was determined that the key targets were tumor necrosis factor(TNF), endothelial growth factor A(VEGFA), serum creatinine(SRC), epidermal growth factor receptor(EGFR), matrix metalloproteinase 9(MMP9), mitogen-activated protein kinase 14(MAPK14), and prostaglandin-endoperoxide synthase 2(PTGS2), which were involved the mitogen-activated protein kinase(MAPK) pathway, advanced glycation end-products(AGE)-receptor for AGE(RAGE) pathway, COVID-19 pathway, and mTOR pathway. This paper elucidated the medication law and mechanism of TCM for the prevention and treatment of epidemic diseases under the guidance of TCM theory of cold pestilence, in order to build a bridge between the theory and modern epidemic diseases and provide reference TCM methods for the prevention and treatment of modern epidemic diseases and ideas for the application of data mining to TCM treatment of modern diseases.
Aconitum
;
Antiviral Agents
;
COVID-19/epidemiology*
;
Calcium Sulfate
;
Communicable Disease Control
;
Communicable Diseases/virology*
;
Creatinine
;
Cyclooxygenase 2
;
Drugs, Chinese Herbal/therapeutic use*
;
Endothelial Growth Factors
;
Epidemics/prevention & control*
;
ErbB Receptors
;
Humans
;
Matrix Metalloproteinase 9
;
Medicine, Chinese Traditional
;
Mitogen-Activated Protein Kinase 14
;
Pinellia
;
SARS-CoV-2
;
TOR Serine-Threonine Kinases
;
Tumor Necrosis Factors
;
COVID-19 Drug Treatment
6.Association of polymorphisms of VEGF and VEGFR1 pathways related genes and risk of pre-eclampsia.
Li LI ; Xiangcui GUO ; Beibei CHEN ; Zhihui GAO ; Juan LIU ; Qiangqing WANG
Chinese Journal of Medical Genetics 2022;39(8):893-897
OBJECTIVE:
To assess the association of single nucleotide polymorphisms (SNPs) of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor 1 (VEGFR1) pathways-related genes and the risk of pre-eclampsia.
METHODS:
In total 178 pregnant women with pre-eclampsia (case group) and 100 healthy pregnant women (control group) during the third trimester were enrolled. The SNPs of VEGF rs3025039, rs2010963 and VEGFR1 rs3812867, rs55875014 and rs722503 loci were determined by PCR-restriction fragment length polymorphism (PCR-RFLP) assay. The levels of serum VEGF and sVEGFR1 were also determined. And their association with pre-eclampsia was analyzed.
RESULTS:
The systolic blood pressure, diastolic blood pressure and sVEGFR1 of the case group were significantly higher than those of the control group, while the VEGF level was significantly lower than that in the control group (P<0.05). Allelic frequencies of the VEGF (rs3025039, rs2010963) and VEGFR1 (rs3812867, rs55875014, rs722503) have fit the Hardy-Weinberg equilibrium (P>0.05). The frequency of T allele of VEGF at rs3025039 locus in the case group was higher than that in the control group (P<0.05). There were significant differences in VEGF at rs3025039 locus under dominant and co-dominant models in case group (P<0.05). Compared with those with CC, the risk was higher in patients with CT or TT genotypes (P<0.05). The systolic and diastolic blood pressure and sVEGFR1 in pre-eclampsia pregnant women with CT or TT genotypes were significantly higher than those with the CC genotype, while their VEGF level was significantly lower (P<0.05). No significant difference was found in allelic frequencies of other four loci between the two groups (P>0.05).
CONCLUSION
Polymorphisms of rs3025039 locus of VEGF gene is associated with the occurrence of pre-eclampsia. The variant at this locus may affect the activity of VEGF and influence the development of pre-eclampsia.
Case-Control Studies
;
Female
;
Genetic Predisposition to Disease
;
Genotype
;
Humans
;
Polymorphism, Single Nucleotide
;
Pre-Eclampsia/genetics*
;
Pregnancy
;
Vascular Endothelial Growth Factor A/genetics*
;
Vascular Endothelial Growth Factor Receptor-1/genetics*
;
Vascular Endothelial Growth Factors/genetics*
7.Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity.
Qing-Fei HAO ; Jing CHEN ; Peng RUAN ; Gao-Pan LI ; Jing ZHANG ; Hao-Ming CHEN ; Hong-Xiang GUO ; Xiao-Juan SUN ; Xiu-Yong CHENG
Chinese Journal of Contemporary Pediatrics 2022;24(11):1207-1212
OBJECTIVES:
To investigate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in the treatment of retinopathy of prematurity (ROP) and the risk factors for recurrence.
METHODS:
A retrospective analysis was performed on the medical data of 159 infants with ROP who were born in the First Affiliated Hospital of Zhengzhou University and underwent anti-VEGF treatment from January 2016 to December 2021. According to the presence or absence of recurrence within the follow-up period after initial anti-VEGF treatment, they were divided into a recurrence group with 24 infants and a non-recurrence group with 135 infants. The medical data were compared between the two groups, and a multivariate logistic regression analysis was used to investigate the risk factors for the recurrence of ROP after anti-VEGF treatment.
RESULTS:
After one-time anti-VEGF treatment, all 159 infants showed regression of plus disease. Recurrence was observed in 24 infants (15.1%) after anti-VEGF treatment, with a mean interval of (8.4±2.6) weeks from treatment to recurrence. The multivariate logistic regression analysis showed that preoperative fundus hemorrhage and prolonged total oxygen supply time were risk factors for the recurrence of ROP (P<0.05), while gestational hypertension was a protective factor (P<0.05).
CONCLUSIONS
Intravitreal anti-VEGF injection is effective for ROP. Preoperative fundus hemorrhage and long duration of oxygen therapy may increase the risk of ROP recurrence, and further studies are needed to investigate the influence of gestational hypertension on the recurrence of ROP.
Female
;
Humans
;
Infant
;
Infant, Newborn
;
Pregnancy
;
Angiogenesis Inhibitors/therapeutic use*
;
Endothelial Growth Factors/therapeutic use*
;
Hemorrhage
;
Hypertension, Pregnancy-Induced
;
Oxygen/therapeutic use*
;
Retinopathy of Prematurity/drug therapy*
;
Retrospective Studies
;
Risk Factors
;
Vascular Endothelial Growth Factor A
8.Effect of Dahuang Zhechong Pills combined with TACE on VEGF, MMP-2, TGF-β1 and immune function of patients with primary liver cancer (blood stasis and collaterals blocking type).
Chao-Ming DAI ; Song JIN ; Ji-Zhou ZHANG
China Journal of Chinese Materia Medica 2021;46(3):722-729
To investigate the effects of Dahuang Zhechong Pills combined with hepatic arterial chemoembolization(TACE) on tumor index and immune function of patients with primary liver cancer(blood stasis and collaterals blocking type), observe its application values in treatment of such patients, and provide effective treatment means for this disease. From June 2019 to December 2019, 79 patients with confirmed primary liver cancer(blood stasis and collaterals blocking type) treated in Wenzhou Hospital of Traditional Chinese Medicine were included in this study, all of which were grouped with random number table method before inclusion in this study. 40 patients in the control group were treated with TACE, while 39 patients in the observation group were treated with Dahuang Zhechong Pills combined with TACE. The efficacy was compared between two groups after 4 weeks of treatment. The immune function indexes of serum CD4~+ cells, CD4~+/CD8~+, CD3~+ cells of the observation group were higher than those in control group after treatment(P<0.05), and tumor indexes such as serum alpha-fetoprotein(AFP), carbohydrate antigen 199(CA199) and glutamic-pyruvic transaminase(ALT), total bilirubin(TBiL) levels were lower than those in the control group, with statistically significant differences(P<0.05). Plasma vascular endothelial growth factor(VEGF), transforming growth factor-β1(TGF-β1), and matrix metalloprotei-nase-2(MMP-2) levels in the observation group were lower than those in the control group after treatment, with statistically significant differences(P<0.05). The total effective rate of the observation group was 87.18%, higher than 67.50% in the control group, and the benefit rate was 94.87% in the observation group, higher than 85.00% in the control group(P<0.05). The total incidence of adverse reactions such as bone marrow suppression, gastrointestinal reaction, fever, renal function injury and peripheral nerve injury in the observation group was 48.72%, lower than 82.50% in the control group, with statistically significant difference(P<0.05). In summary, the combination of Dahuang Zhechong Pills with TACE could improve immunity, protect liver function, and reduce the risk of metastasis and the incidence of adverse reactions from chemotherapy, so it is worth popularizing for patients with primary liver cancer(blood stasis and collaterals blocking type).
Carcinoma, Hepatocellular
;
Chemoembolization, Therapeutic
;
Drugs, Chinese Herbal
;
Humans
;
Liver Neoplasms/drug therapy*
;
Matrix Metalloproteinase 2
;
Transforming Growth Factor beta1
;
Vascular Endothelial Growth Factor A
;
Vascular Endothelial Growth Factors
9.Effect of
Hong-Kui KE ; Shao-Heng TU ; Yu-Jie SHEN ; Qun-Wei QU
Chinese Acupuncture & Moxibustion 2021;41(10):1079-1083
10.Production of high-purity recombinant human vascular endothelial growth factor (rhVEGF165) by Pichia pastoris.
Weijie ZHOU ; Fengmei WU ; Dongsheng YAO ; Chunfang XIE
Chinese Journal of Biotechnology 2021;37(11):4083-4094
Vascular endothelial growth factor (VEGF165) is a highly specific vascular endothelial growth factor that can be used to treat many cardiovascular diseases. The development of anti-tumor drugs and disease detection reagents requires highly pure VEGF165 (at least 95% purity). To date, the methods for heterologous expression and purification of VEGF165 require multiple purification steps, but the product purity remains to be low. In this study, we optimized the codons of the human VEGF165 gene (vegf165) according to the yeast codon preference. Based on the Pichia pastoris BBPB vector, we used the Biobrick method to construct a five-copy rhVEGF165 recombinant expression vector using Pgap as the promoter. In addition, a histidine tag was added to the vector. Facilitated by the His tag and the heparin-binding domain of VEGF165, we were able to obtain highly pure rhVEGF165 (purity > 98%) protein using two-step affinity chromatography. The purified rhVEGF165 was biologically active, and reached a concentration of 0.45 mg/mL. The new design of the expression vector enables production of active and highly pure rhVEGF165 ) in a simplified purification process, the purity of the biologically active natural VEGF165 reached the highest reported to date.
Codon/genetics*
;
Humans
;
Pichia/genetics*
;
Recombinant Proteins/genetics*
;
Saccharomycetales
;
Vascular Endothelial Growth Factor A/genetics*
;
Vascular Endothelial Growth Factors

Result Analysis
Print
Save
E-mail